Table 3. Univariate analysis of outcomes according to the extended-spectrum β-lactamase/carbapenem resistant Enterobacteriaceae fecal carriage.
| Categorical outcome | ESBL-E carriage P, OR (95% CI) | CRE carriage P, OR (95% CI) | Reference group |
|---|---|---|---|
| BSI episodesa | 0.11, 2.95 (0.89 – 7.59) | 0.39, 1.72 (0.56 – 5.78) | Non-ESBL-E/Non-CRE carriage |
| ESBL-E bacteremiaa | 0.69, 1.56 (0.19 – 11.52) | NA | Non-ESBL-E/Non-CRE bacteremic episodes |
| CRE bacteremiaa | 0.83, 0.75 (0.05 – 11.31) | 0.39, 3 (0.28 – 37.67) | Non-ESBL-E/Non-CRE bacteremic episodes |
| Total deaths within 14 daysa | 0.03, 11.31 (1.14 – 112.13) | 0.28, 4.55 (0.27 – 74.91) | Non-ESBL-E/Non-CRE carriage |
| 28-day overall mortalitya | 0.68. 1.25 (0.41 – 3.82) | 0.79, 1.21 (0.34 – 4.26) | Non-ESBL-E/Non-CRE carriage |
| Continuous outcome | (ESBL-E, CRE, Non-ESBL-E/Non-CRE) carriage | ||
| Days of hospitalizationb | P = 0.72 | ||
| Days of antibiotic therapyb | P = 0.84 | ||
aUnivariate logistic regression for categorical outcome. bGeneral linear model/univariate analysis of variance for continuous outcome between three categories of carriage.
ESBL-E, extended-spectrum beta-lactamase-producing Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; OR, odds ratio; CI, confidence interval; NA, not applicable.